All amounts are in US dollars
QUÉBEC CITY, March 28, 2014
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that its shelf registration
statement on Form F-3 previously filed with the Securities and
Exchange Commission (the "SEC") has been declared effective by the
SEC. Under the shelf registration statement, the Company may offer
and sell from time to time, in one or more public offerings in
the United States, up to
$50 million of common shares in one
or more "at-the-market" ("ATM") distribution programs, during a
36-month period. The specifics of any particular ATM share issuance
program, along with the terms and the use of proceeds of any such
common shares offered by the Company will be determined at the time
of any such offering and will be described in detail in a
prospectus supplement or supplements filed with the SEC at the time
of any such offerings.
This press release and the prospectus are not an offer to sell
these securities and they are not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not
permitted. You should not assume that the information contained in
the prospectus and the accompanying prospectus supplement is
accurate on any date subsequent to the date set forth on the front
of these documents or that any information that the Company has
incorporated by reference is correct on any date subsequent to the
date of the document incorporated by reference. The Company's
business, financial condition, results of operations and prospects
may have changed since those dates.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds at
various stages of development. For more information, visit
www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of
its products or product candidates, the ability of the Company to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult
the Company's quarterly and annual filings with the Canadian and
U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The
Company does not undertake to update these forward-looking
statements. We disclaim any obligation to update any such factors
or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.